Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Helge Lund, chair of the Novo Nordisk Board, expressed confidence in the company’s strategy and its ability to execute ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

The gravity-defying stock ... Novo Nordisk’s remarkable ascent, this leadership change represents a sobering reality check about the company’s near-term prospects. The dramatic share price ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Meanwhile, current GLP-1 offerings like Ozempic and Wegovy are also subject to the next round of Medicare drug pricing negotiations in the U.S. “Considering the recent market challenges, the share ...

However, investors are advised not to jump to conclusions regarding acquiring/retaining the stock ... to date, Novo Nordisk shares have plunged 23.1% compared with the industry’s decline of ...

The search for a successor is currently underway. The leadership change comes as Novo Nordisk confronts recent market challenges and a decline in its share price since mid-2024. Despite the company’s ...